Testing a new drug, BGB-58067, in newly diagnosed glioblastoma with MTAP missing
Original title: BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people to check safety and how the drug acts.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing a new drug in people just diagnosed with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary.
Who this trial is for. This trial is for people with a suspected new glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary. They must be set for surgery to take out the tumor. It tests a drug called BGB-58067, including how safe it is and how it acts in the body.
Where it stands. This trial has not reported results. It is measuring how the drug acts in tumor tissue. It is also measuring how many people are alive at 12 months. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: Someone who fits this picture could ask their care team about this trial. The care team can say if it makes sense to look into. They can also help you weigh it against other choices.
What it doesn't mean: This does not mean the drug works. A trial is a test, not a proven treatment. Joining one is not a promise that it will help you. It is not a cure.
Source: ClinicalTrials.gov, August 21, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.